Checking procalcitonin suitability for prognosis and antimicrobial therapy monitoring in burn patients

Author:

Cabral Luís12ORCID,Afreixo Vera3,Meireles Rita1,Vaz Miguel1,Chaves Catarina4,Caetano Marisa5,Almeida Luís6,Paiva José Artur78

Affiliation:

1. Department of Plastic Surgery and Burns Unit, Unidade de Queimados Coimbra University Hospital Centre (CHUC) Av. Bissaya Barreto s/n 3000-075 Coimbra, Portugal

2. Autonomous Section of Health Sciences (SACS) University of Aveiro Aveiro, Portugal

3. CIDMA - Center for Research and Development in Mathematics and Applications, iBiMED, Institute for Biomedicine University of Aveiro Aveiro, Portugal

4. Clinical Pathology Department Coimbra University Hospital Centre (CHUC) Coimbra, Portugal

5. Pharmacy Department Coimbra University Hospital Centre (CHUC) Coimbra, Portugal

6. MedinUP, Department of Pharmacology and Therapeutics, Faculty of Medicine University of Porto Porto, Portugal

7. Department of Emergency and Intensive Care Medicine Centro Hospitalar São João Porto, Portugal

8. Faculty of Medicine University of Porto, Grupo de Infecção e Sépsis Porto, Portugal

Abstract

Abstract Background Due to greater infection susceptibility, sepsis is the main cause of death in burn patients. Quick diagnosis and patient stratification, early and appropriated antimicrobial therapy, and focus control are crucial for patients’ survival. On the other hand, superfluous extension of therapy is associated with adverse events and arousal of microbial resistance. The use of biomarkers, necessarily coupled with close clinical examination, may predict outcomes, stratifying patients who need more intensive care, and monitor the efficacy of antimicrobial therapy, allowing faster de-escalation or stop, reducing the development of resistance and possibly the financial burden, without increasing mortality. The aim of this work is to check the suitability of procalcitonin (PCT) to fulfill these goals in a large sample of septic burn patients. Methods One hundred and one patients, with 15% or more of total body surface area (TBSA) burned, admitted from January 2011 to December 2014 at Coimbra Burns Unit (CBU), in Portugal were included in the sample. All patients had a diagnosis of sepsis, according to the American Burn Association (ABA) criteria. The sample was factored by survival (68 survivors and 33 non-survivors). The maximum value of PCT in each day was used for statistical analysis. Data were summarized by location measures (mean, median, minimum, maximum, quartiles) and dispersion measures (standard error and range measures). Statistical analysis was performed with SPSS© 23.0 IBM© for Windows©. Results There were statistically significant differences between PCT levels of patients from the survivor and non-survivor groups during the first and the last weeks of hospitalization as well as during the first week after sepsis suspicion, being slightly higher during this period. During the first 7 days of antimicrobial therapy, PCT was always higher in the non-survivor, still without reaching statistical significance, but when the analysis was extended till the 15th day, PCT increased significantly, rapidly, and steadily, denouncing therapy failure. Conclusion Despite being not an ideal biomarker, PCT proved to have good prognostic power in septic burn patients, paralleling the evolution of the infectious process and reflecting the efficacy of antimicrobial therapy, and the inclusion of its serial dosing may be advised to reinforce antimicrobial stewardship programs at burn units; meanwhile, more accurate approaches are not available.

Publisher

Oxford University Press (OUP)

Subject

Critical Care and Intensive Care Medicine,Dermatology,Biomedical Engineering,Emergency Medicine,Immunology and Allergy,Surgery

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Surviving Sepsis After Burn Campaign;Burns;2023-11

2. AACC Guidance Document on the Clinical Use of Procalcitonin;The Journal of Applied Laboratory Medicine;2023-05-01

3. Procalcitonin As a Biomarker and Mediator of Sepsis: Implications for Critical Care;Biomarkers in Trauma, Injury and Critical Care;2023

4. Clinical relevance of serum procalcitonin in patients with aneurysmal subarachnoid hemorrhage;Experimental and Therapeutic Medicine;2022-09-06

5. Procalcitonin As a Biomarker and Mediator of Sepsis: Implications for Critical Care;Biomarkers in Trauma, Injury and Critical Care;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3